Biolife Plasma Services
BioLife Plasma Services, a wholly owned Takeda subsidiary, operates 238 U.S. plasma donation centers that collect paid-donor plasma via plasmapheresis and supply it to Takeda for manufacturing therapies that treat primary immunodeficiency and other rare diseases.
- Company typePrivate
- Founded1941
- HeadquartersMentor, United States
- Headcount5,001–10,000
- GTM typeB2C
- OfferingServices
What Biolife Plasma Services does
BioLife Plasma Services L.P. is a U.S. private plasma collection company and a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Founded on Takeda's plasma operations dating to 1941, BioLife operates a network of 238 state-of-the-art plasma donation centers across 40+ U.S. states, employing more than 10,000 staff and serving hundreds of thousands of donors monthly. The company collects human plasma via plasmapheresis — an automated process that separates plasma from whole blood and returns red blood cells to the donor — and supplies substantially all collected plasma to its parent Takeda for use in manufacturing plasma-derived therapies that treat primary immunodeficiency (PI) and other rare diseases. The U.S. plasma industry, of which BioLife is one of three major players alongside CSL Plasma and Grifols, supplies approximately 70% of the world's blood plasma and generated $6.2 billion in U.S. plasma exports in 2024.
BioLife's product ecosystem extends beyond physical plasma collection to include a donor-facing mobile application for iOS and Android, a Takeda ID-authenticated online portal, a BioLife Debit Mastercard for compensation disbursement, a loyalty rewards program, and a Buddy Bonus referral incentive. The company has integrated third-party AI tooling (Paradox AI's "Olivia" chatbot), identity management (Okta), personalization (Evergage), and privacy compliance (OneTrust) into its digital properties. Donors are compensated on a usage-based model — approximately $70 per visit for regular donors and up to $800 for new donors based on center location — funded by the downstream sale of plasma-derived therapies by Takeda. BioLife's stated value proposition centers on the fact that plasma cannot be manufactured synthetically, meaning patients with rare diseases depend on compensated donors for their therapies.
The business model is effectively a vertically integrated supply arm within Takeda's plasma-derived therapies value chain: BioLife collects plasma from paid individual donors, transfers the raw material to its parent, and Takeda fractionates it into immunoglobulin, albumin, and other therapeutic products sold to healthcare providers and patients. The company's GTM is direct-to-consumer / self-serve PLG, with donors signing up online or via mobile app and visiting physical donation centers. BioLife markets through a multi-channel digital presence (website, mobile apps, Facebook, Instagram, LinkedIn, YouTube, Pinterest) and a referral program, while remaining operationally U.S.-domestic. Recent strategic activity includes a February 2026 nationwide network optimization that resulted in the closure of two of three Wyoming centers, signaling a maturity-phase footprint rationalization rather than expansion.
Biolife Plasma Services firmographics
Firmographics- Name
- Biolife Plasma Services
- Legal name
- BioLife Plasma Services L.P.
- Website
- https://biolifeplasma.com
- Company type
- Private
- Founded year
- 1941
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- BioLife Plasma Services, a wholly owned Takeda subsidiary, operates 238 U.S. plasma donation centers that collect paid-donor plasma via plasmapheresis and supply it to Takeda for manufacturing therapies that treat primary immunodeficiency and other rare diseases.
- Ownership category
- akta.pro rank
Biolife Plasma Services industry classification
Industry- Product category
- Plasma Collection Services
- NAICS
- Blood and Organ Banks (621991)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Plasma Collection & Donor Services (Plasmapheresis Centers) (HLAIAHAH)
- akta.pro secondary industry
- Plasma-Derived Therapy Fill-Finish & Packaging (HLAIAHAJ)
Keywords
Where Biolife Plasma Services is headquartered
LocationHeadquarters
- HQ city
- Mentor
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Biolife Plasma Services business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- Plasma Collection Services: Collects plasma from paid donors at donation centers across the U.S. The collected plasma is supplied to parent company Takeda Pharmaceutical for manufacturing plasma-derived therapies and biopharmaceutical products.
- Donor Compensation Program: Pays donors approximately $70 per visit for plasma donations. Compensation funded by revenue from plasma product sales to pharmaceutical partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | New Donor Incentive Program - up to $800 for first-time donors |
| Usage-based | Pay-as-you-go | Regular Donor Compensation - approximately $70 per donation visit |
| Usage-based | Pay-as-you-go | Buddy Bonus Referral Program - additional compensation for referring friends |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels9 records
Biolife Plasma Services product offering
Product offeringCore offering
BioLife Plasma Services operates 238 state-of-the-art plasma donation centers across the United States where it collects source plasma from paid individual donors using plasmapheresis technology. The collected plasma is supplied to its parent company, Takeda Pharmaceutical, which uses it to manufacture plasma-derived therapies and biopharmaceutical products for patients with primary immunodeficiency and other rare diseases. Supporting services include a mobile app, online scheduling portal, BioLife Debit Card compensation, Buddy Bonus referral program, and a donor Loyalty Program.
Product overview
BioLife Plasma Services operates a plasma donation platform comprising 238 state-of-the-art donation centers across the United States, with over 80 years of industry expertise as part of Takeda Pharmaceutical. The core offering is plasma collection services using plasmapheresis, which produces therapies for patients with primary immunodeficiency and other rare diseases. The product ecosystem includes a mobile application for appointment scheduling and account management, a BioLife Debit Card for donor compensation, a Buddy Bonus referral incentive program, and a loyalty rewards program. All collected plasma is supplied to Takeda Pharmaceutical for manufacturing lifesaving plasma-derived medicines.
Differentiator
Problem solved
Functional benefit
Products and services
- BioLife Plasma Donation Services
- BioLife Mobile Application
- BioLife Debit Card
- Buddy Bonus Referral Program
- Loyalty Program
Quantifiable outcome
- 130 donations are needed to treat 1 PI patient for one year
- +1 more outcomes
Companies that use Biolife Plasma Services
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
Biolife Plasma Services technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability2 records
Feature3 records
Biolife Plasma Services partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Takeda Pharmaceutical Company LimitedcoreBioLife Plasma Services L.P. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. BioLife collects plasma from donors at its U.S. centers, which is then used by Takeda to manufacture plasma-derived therapies and lifesaving medicines for patients with rare diseases.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Biolife Plasma Services competitors and assessment
Company assessmentOthers
- Vitalant: Large U.S. nonprofit community blood collector that also collects source plasma for fractionation; comparable operationally to BioLife's center-based model but competes only tangentially as a non-paid alternative supplier.
- American Red Cross Biomedical Services: Largest U.S. blood and plasma collection nonprofit; comparable activity (volunteer-based plasma/blood collection) but operates on a non-paid donor model and is not a direct competitor for BioLife's paid donor base.
Direct peers
- Kedrion Biopharma: Global plasma-derived therapy manufacturer that also operates plasma collection operations in the U.S. and Europe; comparable as both a fractionator and a collector feeding into its own therapeutic portfolio.
- Grifols Plasma: Plasma collection arm of Grifols, operating a large U.S. donation center network that supplies plasma for Grifols' own fractionation into plasma-derived therapies; direct competitor for donors and structurally analogous to BioLife's model.
- CSL Plasma: Subsidiary of CSL Behring; operates the largest network of plasma donation centers in the world with several hundred U.S. locations, directly competing with BioLife for paid plasma donors and feeding CSL Behring's fractionation business.
- Octapharma Plasma: U.S. plasma collection subsidiary of Octapharma AG, running ~190 donation centers that supply raw plasma for Octapharma's plasma-derived therapeutic products; directly comparable in scale, donor model, and vertical integration.
Broad incumbents
- Takeda Pharmaceutical Company Limited: BioLife's parent company and a global top-10 pharmaceutical firm; operates the broader plasma-derived therapies (PDT) and rare disease franchise that BioLife's collection volume feeds into.
- Grifols S.A. Spanish multinational plasma fractionator and collector; comparable as the integrated incumbent whose U.S. plasma network directly competes with BioLife and whose therapeutics represent adjacent end-market.
- CSL Behring: Parent of CSL Plasma and a global leader in plasma-derived therapies; relevant as the vertically-integrated incumbent whose collection arm is BioLife's most direct competitor.
Emerging players
- ADMA Biocenters: U.S. plasma collection business operated by ADMA Biologics; smaller, more niche footprint than BioLife, but materially overlaps in donor experience, collection technology, and supply of specialty hyperimmune plasma.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Biolife Plasma Services social profiles
Digital presenceBiolife Plasma Services compliance and trust
Trust signalCompliance5 records
Biolife Plasma Services financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biolife Plasma Services leadership team
Management profileNumber of profiles
Biolife Plasma Services funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biolife Plasma Services M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biolife Plasma Services
What does Biolife Plasma Services do?
BioLife Plasma Services operates 238 state-of-the-art plasma donation centers across the United States where it collects source plasma from paid individual donors using plasmapheresis technology. The collected plasma is supplied to its parent company, Takeda Pharmaceutical, which uses it to manufacture plasma-derived therapies and biopharmaceutical products for patients with primary immunodeficiency and other rare diseases. Supporting services include a mobile app, online scheduling portal, BioLife Debit Card compensation, Buddy Bonus referral program, and a donor Loyalty Program.
Is Biolife Plasma Services a public or private company?
Biolife Plasma Services is a private company. It is classified as corporate owned and is currently operating.
When was Biolife Plasma Services founded?
Biolife Plasma Services was founded in 1941. It employs 5,001 to 10,000 people.
Where is Biolife Plasma Services based?
Biolife Plasma Services is headquartered in Mentor, United States, in the North America region.
How does Biolife Plasma Services make money?
Two revenue lines are on record. Plasma Collection Services are the primary driver. The others are donor Compensation Program.
Who are Biolife Plasma Services's main competitors?
Others on record are Vitalant and American Red Cross Biomedical Services. Direct peers are Kedrion Biopharma, Grifols Plasma, CSL Plasma and Octapharma Plasma. Broad incumbents are Takeda Pharmaceutical Company Limited, Grifols S.A. and CSL Behring. ADMA Biocenters is listed as an emerging player.
Does Biolife Plasma Services have an API?
No public API is recorded for Biolife Plasma Services.
What industry is Biolife Plasma Services in?
Biolife Plasma Services's product category is Plasma Collection Services. Its primary akta.pro industry code is HLAIAHAH, Plasma Collection & Donor Services (Plasmapheresis Centers), with a secondary code of HLAIAHAJ, Plasma-Derived Therapy Fill-Finish & Packaging. Its NAICS code is 621991 and its SIC code is 2836.